All the news Showing 10 of 83 articles from: Ns5A inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Mylan Launches Generic Harvoni® (Ledipasvir/Sofosbuvir) Under the Brand Name MyHep LVIR™ in India Mylan press release / 08 January 2016 AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® AbbVie press release / 02 December 2015 NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4 Manual Items / 16 October 2015 U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs Bristol-Myers Squibb / 07 October 2015 Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes Gilead press release / 21 September 2015 Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study") Achillion press release / 18 September 2015 Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission Bristol-Myers Squibb press release / 15 September 2015 Adding ribavirin to Harvoni for hepatitis C increases side effects but not efficacy HIVandHepatitis.com / 29 June 2015 Achillion partners with J&J to develop hepatitis C drugs Reuters / 20 May 2015 FDA to review re-submitted Bristol-Myers hepatitis C drug Reuters / 12 March 2015 ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive